[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-bronchiale\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-bronchiale":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,45,76,99,124,153,192,223,249,273,315,341,366,394],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100630610","fixed-triple-inhaled-combination-in-asthmatic-patients-in-a-real-life-setting-strength-100630610",false,"NCT07489911","Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)","A Prospective Non-Interventional Real-world Study Assessing the Effectiveness of Extrafine BDP\u002FFF\u002FG HS Single Inhaler Triple Therapy (SITT) on Symptom Scores in Asthma Patients After 6 Months Treatment","STRENGTH","INCLUSION CRITERIA:\n\n* Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion\n* Patients ≥ 18 years of age in ambulatory care\n* Uncontrolled asthma according to the physician's clinical assessment despite the use of:\n\n  1. LABA and high dose ICS or\n  2. LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.\n* Patients who are eligible for the use of Trimbow 172\u002F5\u002F9 μg pMDI according to the SmPC :\n\n  1. at least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months\n  2. uncontrolled asthma (ACT≤15) or partially controlled asthma (15\\\u003CACT\\\u003C20)\n  3. FEV1\\\u003C80% at baseline\n* Inhaled asthma therapy was changed to Trimbow 172\u002F5\u002F9 μg pMDI no more than 1 week prior to OR on the day of study inclusion\n* Patient provided written, informed consent to study participation\n\nEXCLUSION CRITERIA:\n\n* Participation in any clinical trial within 30 days prior to enrolment\n* Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment\n* Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND\u002FOR another important clinical situation that may interfere with patient's compliance with the treatment.\n* Continuous use of oral (\\>5 mg prednisolone\u002Fday OR \\>4 mg methylprednisolone\u002Fday) OR intravenous corticosteroids\n* Use of continuous oxygen therapy\n* Any malignant disease in the last 5 years\n* Tuberculosis (active or anamnestic)\n* Actual or previous use of biologics for asthma treatment in the past 12 months\n* All exclusion criteria listed in Trimbow 172\u002F5\u002F9 μg pMDI SmPC","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients at GINA steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and adherence.",[25,26,27],"Asthma","Asthma Patients","Asthma Bronchiale",[29,25,30,31],"Single Inhaler Triple Therapy","SITT","Trimbow","RECRUITING","2026-03-18",{"date":35,"type":36},"2026-03-24","ACTUAL",{"date":38,"type":36},"2024-11-04",{"date":40,"type":21},"2026-07",{"name":42,"class":43},"Chiesi Slovenija, d.o.o.","INDUSTRY",18,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100620943","bronchodilator-response-in-copd-and-asthma-correlation-between-spirometry-ios-indices-and-dyspnea-relief-100620943","NCT07364188","Bronchodilator Response in COPD and Asthma: Correlation Between Spirometry, IOS Indices, and Dyspnea Relief","Inclusion Criteria:\n\n* Both asthma and COPD patients:\n\n  1. Written informed consent.\n  2. FEV1\u002FForced Vital Capacity (FVC) \\\u003C0.7 at baseline (7)\n  3. Visual Analog Scale (VAS) dyspnea score ≥10 (0-100, 100 max) (25,26).\n* Asthma: Doctor diagnosed asthma\n\n  1\\. less than 10 packyears.\n* COPD: Doctor diagnosed COPD with FEV1\u002FFVC \\\u003C0.7 post-bronchodilation 1. Smokers or ex-smokers with ≥10 packyears\n\nExclusion Criteria:\n\n* Patients aged less than 18 years old.\n* Not able to perform spirometry or impulse oscillometry.\n* Cognitive disorders and not able to answer Asthma Control Questionnaire (ACQ), VAS dyspnea score, and COPD Assessment Test (CAT) score (25-28).\n* Short-acting beta-agonists 6 h, long-acting beta-agonists 2 days, short-acting anti-muscarinic agent 12 h, Long-acting anti-muscarinic agents 2 days.\n* Comorbidities with significant influence on dyspnea eg. bronchiectasis, ILS, mb. Cordis, lung resection, anemia, and active malignant disease\n* BMI ≥40 kg\u002Fm2.",{"count":52,"type":21},120,"A bronchodilator reversibility test is widely used in the diagnosis and management of obstructive lung diseases.\n\nBronchodilators relieve symptoms in asthma and COPD. Traditionally, their effectiveness has been assessed using spirometric indices, particularly FEV₁. However, changes in FEV₁ often do not correlate well with patients' subjective experience of dyspnoea relief or with changes in small airway function.\n\nImpulse oscillometry (IOS) provides an effort-independent assessment of respiratory mechanics during tidal breathing and is more sensitive to small airway dysfunction than spirometry. Despite this, the clinical utility of IOS in routine COPD and asthma assessment remains underexplored, and its relationship to both spirometric response and symptom relief is not fully established, and the Minimal Clinically Important Difference (MCID) for IOS parameters has not been firmly established. Determining the MCID is essential for interpreting individual patient responses in a clinically meaningful way and for guiding treatment decisions in both research and practice.\n\nHypothesis \\& Aims\n\nIn patients with either asthma or COPD baseline values and bronchodilator responses are compared. More specifically, this study aims to:\n\n1. assess baseline correlations: Evaluate the correlation between ΔX5-baseline (EFL expiratory flow limitation=small airway collapse during expiration), RV\u002FTLC-baseline, X5-average at baseline, FEV1-baseline, VAS-dyspnea at baseline, and ACQ-6-baseline.\n2. compare bronchodilator responses across methods: Examine the correlation between bronchodilator-induced changes in FEV₁ and IOS parameters (including both average and delta values) and explore their relationship with short-term changes in dyspnea.\n3. establish clinical relevance: Determine the MCID for key IOS variables using both anchor-based and distribution-based approaches, anchored to perceived changes in lung symptoms.",[27,55,56,57,58,59],"COPD","Bronchodilation","Spirometry","Impedance","Small Airways Disease",[61,55,62,63,64],"asthma","Correlation","Bronchodilator response","MCID","NOT_YET_RECRUITING","2026-01-23",{"date":68,"type":36},"2026-01-26",{"date":70,"type":21},"2026-02-01",{"date":72,"type":21},"2027-12-31",{"name":74,"class":75},"Allergi- og Lungeklinikken, Elsinore","NETWORK",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100580367","pilot-study-for-the-application-of-low-power-external-bioelectronic-devices-in-the-diagnosis-of-bronchial-asthma-100580367","NCT06836375","Pilot Study for the Application of Low Power External Bioelectronic Devices in the Diagnosis of Bronchial Asthma.","Estudio Piloto Para la aplicación de Dispositivos bioelectrónicos Externos de Baja Potencia en el diagnóstico de Asma Bronquial","Inclusion Criteria:\n\n* Male or female, aged \\>= 18 and \\\u003C 65.\n* Ability to access applications on mobile device, technical understanding and minimal technological skills\n* Subject has provided informed consent and is willing to comply with the study procedures.\n\nExclusion Criteria:\n\n* Subject does not consent to the study\n* Subject does not comply with inclusion criteria\n* Subject has a known allergy to medical adhesives","65 Years",{"count":85,"type":21},50,"The objective of this study is to detect the acoustic signals generated by the respiratory system on asthma patients using an acoustic sensor and retrospectively use these signals to identify the characteristics that differentiate patients with asthma and healthy subjects.",[27],[25],"2025-08-14",{"date":91,"type":36},"2025-08-19",{"date":93,"type":21},"2025-09-27",{"date":95,"type":21},"2027-02-27",{"name":97,"class":43},"Acurable Ltd.",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":98},"100596784","long-term-effect-of-dupilumab-in-n-erd-100596784","NCT07049978","Long-term Effect of Dupilumab in N-ERD","Long-term Effect of Dupilumab on Acetylsalicylic Acid (ASA) Intolerance and Its Mechanisms in Patients With Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease (N-ERD)","Inclusion Criteria:\n\n* Participated previously in our preliminary study (EK 1044\u002F2020) and continued Dupilumab treatment since then. Long-term use of Dupilumab since the preliminary study will be assessed based on patient self-report, as there is currently no clinical test or laboratory parameter available to objectively verify treatment duration.\n* Signed and dated informed consent has been obtained\n* Current therapy with Dupilumab\n\nExclusion Criteria:\n\n* Pregnancy (as determined by urine ß-HCG test)\n* Clinically significant abnormal laboratory values and active infection (Tbc, HIV, hepatitis A\u002FB\u002FC)\n* History of malignancy or immunodeficiency\n* Chronic obstructive lung disorders (COPD), other obstructive lung disorders (bronchiolitis)\n* Need for systemic corticosteroid therapy 1 month prior to screening visit\n* Eosinophilic pneumonia and Churg-Strauss Syndrome\n* Previous anaphylaxis and contraindications against ASA as outlined in the official prescribing information.",{"count":107,"type":21},30,"This prospective observational study investigates the long-term effects of Dupilumab in patients with NSAID-exacerbated respiratory disease (N-ERD). The study assesses changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.",[110,111,112,27,113],"NSAID-Induced Asthma","NSAIDs Hypersensitivity","Chronic Rhinosinusitis (CRS)","Nasal Polyposis","2025-07-03",{"date":116,"type":36},"2025-07-08",{"date":118,"type":21},"2025-07-01",{"date":120,"type":21},"2026-06-30",{"name":122,"class":123},"Medical University of Vienna","OTHER",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":135,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":98},"100596488","effect-of-tezepelumab-on-barrier-function-in-severe-asthmatic-patients-with-and-without-comorbid-chronic-rhinosinusitis-with-nasal-polyps-100596488","NCT07046117","Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps","Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps - an Exploratory Study","Tezebarrier","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Age 18-99 years and willing to participate in the study\n3. Have a recorded clinical diagnosis of asthma (ICD-10 Code: J45)\n4. Undergo severe asthma treatment according to GINA\u002FDAL treatment step 4 or 5\n5. Meet the requirements for treatment of severe asthma with Tezepelumab defined as:\n\n   * severe asthma that remains uncontrolled despite a high dosage of ICS\u002FLABA, or that requires a high dose to prevent it from becoming uncontrolled. One of the following criteria needs to be fulfilled:\n\n     * ACT \\\u003C20, ACQ\\>0.75\n     * During the last 12 months 2 courses of OCS for at least 3 days due to severe asthma symptoms\n     * During last 12 months one exacerbation requiring hospitalization\n     * Lung function: FEV1 \\\u003C80% predicted\n   * FeNO ≥ 20 ppB\n   * had either ≥250 eosinophils \u002Fµl measured in the blood OR measurement of blood eosinophils ≥150 cells during reduction of OCS dosing or high dose ICS and\u002For one measurement of sputum eosinophils \\> 2% or BAL eosinophils \\> 2%\n   * Group with polyps: Presence of nasal polyps as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines\n6. mucus score of ≥ 1\n7. Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 3 half-lives or 3 months have passed (whichever is longer)\n\nExclusion Criteria:\n\n* 1\\. Patients with current therapy with biologics as well as therapy with biologics 12 weeks (3 half-lives) before the start of the study or history of therapy with tezepelumab 2. Pregnancy (as determined by urine pregnancy test) 3. Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity or to perform bronchoscopy 4. Patients with any other confounding underlying lung disorder including but not limited to:\n\n  * Bronchiectasis, pulmonary fibrosis, emphysema, primary ciliary dyskinesia\n  * Cystic fibrosis, any known parasitic infections and lung cancer\n\n    5\\. Patients with other causes of nasal polyps than Type 2 CRS inflammation 6. Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA) allergic bronchopulmonary aspergillus and hypereosinophilic syndrome 7. Contraindications for endobronchial and\u002For transbronchial biopsy. 8. A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study 9. Patients with clinically meaningful comorbidity as determined by the evaluating committee 10. Immunosuppressive treatment (e.g. cyclosporine) 11. Drug and alcohol abuse 12. Current smoker and former smokers if stopped smoking \\\u003C6 months","99 Years",{"count":134,"type":21},20,"INTERVENTIONAL",[137],"NA","In this study, we will investigate the effect of tezepelumab on the epithelial barrier function of the upper and lower airways in patients suffering from severe asthma with and without chronic rhinosinusitis with nasal polyps. This will be achieved by analysis of epithelial barrier function upon challenge with various harmful substances (e.g. cigarette smoke extract, allergens) in cultured primary respiratory tract epithelial cells. Furthermore we will assess changes in clinical parameters, cellular composition and inflammatory mediators.",[27,140],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",[61,142,143,144,145],"chronic rhinosinusitis with nasal polyps","tezepelumab","epithelial barrier","airways","2025-06-30",{"date":118,"type":36},{"date":149,"type":21},"2025-10-01",{"date":151,"type":21},"2028-08-01",{"name":122,"class":123},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":135,"phases":163,"briefSummary":164,"conditions":165,"keywords":171,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":98},"100595747","supporting-patients-starting-new-medicines-evaluating-the-mycare-start-service-in-switzerland-100595747","NCT07036471","Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland","Evaluation of the myCare Start Service to Support Patients Starting a New Medicine in Switzerland: A Hybrid Type II Effectiveness-implementation Study","myCare Start-I","Patients\n\nInclusion Criteria:\n\n* Must have mandatory basic health insurance in Switzerland\n* Must have been newly prescribed one or more new long-term medications in accordance with the following chronic conditions: cadisovascular diseases (incl. hyertension and thromboprophylaxis), diabetes, hyperlipidemia, depression, respiratory illness (asthma and COPD)\n* Must be able to self-manage treatment (i.e. they live at home without any support to manage their medication, exception: patient uses a pill dispenser and fills it in by him-\u002Fherself)\n* Must be able to understand language spoken by pharmacy staff and can read and understand study documents (French, German, English)\n* Must understand and are willing to consent to the myCare Start-I study (including the agreement on self-reported questionnaires and collection of health care data via their health insurance company)\n* in the intervention arm, patients must receive the myCare Start service\n\nFor this study, a new medication is a medication that has not been previously dispensed to the patient. This includes one or more new medications for a new diagnosis and or new medications for pre-existing diagnosis of a long-term condition. Included in this working definition:\n\n* The new medication is indicated for one of the five long-term diseases listed above\n* Patient has never had this active ingredient dispensed before (patient still considered eligible if they have received a small initial sample pack from their physician) or restarts an active ingredient after a period of interruption of at least 12 months (time period to be reported by the patient). Please note that for patients, that have already started a sample pack of medication the myCare Start Consultation One can start upon first dispensation at the pharmacy, there is no need to wait 7-14 days.\n* The new active ingredient can be part of a combo preparation (e.g. a diuretic added to an ACE inhibitor into the same preparation)\n* Patient has had no change in active ingredient but has an important change in treatment administration, such as:\n\n  * Change of galenic form (e.g. two different types of inhalators for asthma\u002FCOPD)\n  * Intensification of dosage regiment (e.g. twice a day instead of once a day)\n* The following change is not considered as medication initiation:\n\n  * New dosage of already known active ingredient (e.g. dose escalation of antidepressants)\n  * Simplification of administration mode (e.g. metformin 1000 mg 1-0-0 instead of 500 mg 1-0-1; change in antihypertensive drug regiment in elderly patients having vertigo in the morning: 0-0-X instead of X-0-0)\n\nExclusion Criteria:\n\n* Patients participating or having participated in an education program about their disease or treatment in the last 3 months, led by healthcare providers such as physicians, nurses, pharmacists or other (e.g. education provided by nurses for type I diabetes patients)\n\nPhysicians:\n\nInclusion criteria\n\n\\- Any physician treating a patient for one of the five long-term illnesses listed above is eligible to refer the patient to a pharmacy providing myCare start.\n\nPharmacies:\n\nInclusion criteria:\n\n* Have to be enrolled into the myCare Start service and comply to the requirements of the pharmacy quality system management of having access to a private consultation room or area\n* Must agree to participate in the research study, including the recruitment of control patients and the delivery of the myCare Start service to intervention patients.",{"count":162,"type":21},1600,[137],"In Phase B, the aim is to evaluate the myCare Start service in routine care within the ambulatory primary care medicine and community pharmacy setting in Switzerland. A Type II hybrid effectiveness-implementation study will be conducted to evaluate the effectiveness (improvement in adherence), cost-effectiveness and implementation of the service. This evaluation will allow us to build the necessary contextual relevant evidence base to support sustainable funding of the service in the long term.",[166,167,168,55,27,169,170],"Cardio-vascular Disease","Depression Disorders","Diabetes","Hyperlipidaemia","Medication Initiation for Long-term Conditions",[172,173,174,175,176,177,178,179,180,181,182],"patient adherence","medication adherence","medication initiation","long-term treatment","implementation science","interprofessional collaboration","outpatient care","community pharmacy","general practitioner","cost-effectiveness","medication adherence support programme","2025-06-16",{"date":185,"type":36},"2025-06-25",{"date":187,"type":21},"2025-06",{"date":189,"type":21},"2027-01",{"name":191,"class":123},"University of Geneva, Switzerland",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":200,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":205,"conditions":206,"keywords":209,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":98},"100595334","methacholine-challenge-test-in-school-children-withwithout-asthma-riska-100595334","NCT07031102","Methacholine Challenge Test in School Children With\u002FWithout Asthma RISKA","RISKA: Respiratory Irritability With School Kids With\u002FWithout Asthma - Assessment of Methacholine Responsiveness in Pediatric Asthma: A Comparative Study With Healthy Controls","RISKA","Inclusion Criteria: Healthy Controls\n\n* • Aged 7-15 years, both sexes\n\n  * No diagnosis of asthma in childhood\n  * No inhaled asthma medication during the previous 2 years\n  * No wheezing or shortness of breath during the previous 2 years\n  * Written informed consent from the participant and guardian\n\nInclusion Criteria: Children with Asthma\n\n* Aged 7-15 years, both sexes\n* Physician-diagnosed asthma (ICD-10 codes J45.0\u002FJ45.1\u002FJ45.9)\n* Inhaled corticosteroid treatment for at least 6 months\n* Either:\n\n  * Well-controlled asthma (c-ACT\u002FACT score ≥20) and no clinical need to intensify medication, or\n  * Poorly controlled asthma with physician-confirmed need for intensified asthma medication\n\nExclusion Criteria:\n\n* • Premature birth before 32 gestational weeks\n\n  * Other chronic cardiopulmonary or neurological conditions affecting airways (excluding asthma)\n  * Severe underlying illness such as malignancy\n  * Beta-blocker medication\n  * Active immunological disease",true,"7 Years","15 Years",{"count":204,"type":21},260,"The study includes a pre-study telephone interview with healthy controls to assess their eligibility for participation. During the study visit, a background information form and an asthma questionnaire are completed. At the study visit, a methacholine challenge test measuring airway hyperresponsiveness and an exhaled nitric oxide measurement are performed. The effect of medication intensification in asthma patients is further assessed through a telephone interview 1-2 months after the medication adjustment.",[27,207,208],"Lung Function Tests","Bronchial Hyperresponsiveness",[25,210,211,212,213],"Lung function test","children","Methacholine challange test","Bronchial provocation test","2025-06-12",{"date":216,"type":36},"2025-06-22",{"date":218,"type":36},"2024-11-06",{"date":220,"type":21},"2027-12",{"name":222,"class":123},"Helsinki University Central Hospital",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":248},"100590350","investigation-of-the-respiratory-profile-of-patients-with-obstructive-pulmonary-disease-asthma-copd-100590350","NCT06966271","Investigation of the Respiratory Profile of Patients With Obstructive Pulmonary Disease (ASTHMA, COPD)","Investigation of the Relationship Between the Respiratory Profile of Patients With Obstructive Pulmonary Disease and the Effectiveness of the Inhalation Therapies","OPTIPULM","Primary Outcome Measure:\n\nEstimated Lung Deposition of Inhaled Medication (% of Emitted Dose): The proportion of the inhaled drug dose predicted to deposit in the lungs, calculated via computer modeling using each participant's individual pulmonary function curve and inhalation parameters.\n\nInclusion criteria:\n\n* Diagnosed obstructive pulmonary disease (asthma or COPD) confirmed by a pulmonologist.\n* Proper use of inhalation device after training.\n* Routine pulmonary function test performed during medical visit.\n* Ambulatory (non-hospitalized) patient.\n* Age over 18 years.\n* Mentally competent and able to consent.\n\nExclusion criteria:\n\n* Failure to meet any of the inclusion criteria.\n* Inability to complete the relevant parts of the questionnaire.\n* Refusal to consent to participation.\n* Presence of untreated severe chronic illness.\n* Invalid or improperly conducted pulmonary function test.",{"count":232,"type":21},150,"The primary aim of the OPTIPULM study is the evaluation of recorded pulmonary function curves and, based on them, the computer modelling of lung deposition for the individually used or potentially applicable inhalation drugs. The secondary aims include assessing the patients' inhalation device usage and providing recommendations for its optimization based on the recorded breathing curves and deposition calculations. The study also compares results across different flow rates and device resistances, aiming to identify the device with the highest modelled lung deposition for each patient.\n\nUnderstanding and Improving Inhalation Therapy in Lung Disease The OPTIPULM study looks at how well inhaled medications reach the lungs of people living with asthma or COPD (chronic obstructive pulmonary disease). It aims to improve treatment by helping doctors choose the best inhaler for each patient based on how they breathe.\n\nEvery patient breathes differently, and not all inhalers work the same way. Sometimes the medicine doesn't reach deep enough into the lungs, which can make treatment less effective. This study helps doctors better understand which device works best for each individual.\n\nWhat happens during the study? No new treatments or changes to medication are made.\n\nPatients do a regular breathing test (like blowing into a tube). A computer program uses this breathing data to simulate how much medicine reaches the lungs with different inhalers.\n\nDoctors can then make more personalized choices for inhalation therapy.\n\nWho can take part? Adults with asthma or COPD who are able to use their inhaler correctly and complete a breathing test.\n\nWhat is the benefit? Although the study does not change treatments directly, it helps improve future care by identifying the best-matching inhaler for each patient. This can lead to better symptom control and fewer exacerbations.",[27,55],[236,237,238],"inhalation therapy","computer modelling","aerosol drug delivery","2025-05-02",{"date":241,"type":36},"2025-05-11",{"date":243,"type":36},"2025-01-01",{"date":245,"type":21},"2025-12-30",{"name":247,"class":43},"Tradeflex Ltd",7,{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":201,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":135,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":98},"100585972","animated-video-and-booklet-education-for-improving-asthma-control-and-medication-compliance-in-children-100585972","NCT06909318","Animated Video and Booklet Education for Improving Asthma Control and Medication Compliance in Children","The Effect of Animated Video and Booklet Education on Asthma Control and Medication Compliance in Children With Asthma: A Randomized Controlled Study","Inclusion Criteria:\n\n* Children aged between 7 and 11 years\n* Diagnosed with asthma by a pediatric allergy specialist\n* Mild or moderate asthma severity according to GINA criteria\n* No communication difficulties\n* Have not received any asthma-related education outside of routine clinical care during the study period\n* No known mental or neurological disabilities\n* No serious chronic illness other than asthma (e.g., cardiac, neurological conditions)\n* At least one parent owns a smartphone or tablet\n* Child and parent volunteer to participate and provide informed consent\n\nExclusion Criteria:\n\n* Children younger than 7 or older than 11\n* Severe persistent asthma according to GINA criteria\n* Communication difficulties\n* Prior asthma education outside of routine clinical care\n* Children with cognitive or neurological impairments\n* Children who frequently require emergency care due to asthma exacerbations\n* Families without access to communication tools (e.g., no internet, smartphone, or unable to communicate)\n* Lack of consent from either the child or parent","11 Years",{"count":258,"type":21},66,[137],"Asthma is a chronic inflammatory disease that causes wheezing, coughing, and shortness of breath, and it is a significant cause of morbidity and mortality in the pediatric population. The World Health Organization (WHO) estimated that 262 million people were affected by asthma in 2019, with 461,000 asthma-related deaths annually. In Turkey, the prevalence of asthma in children aged 6-12 ranges from 2% to 16%. Inadequate asthma control in children is often associated with poor medication adherence, lack of knowledge, misbeliefs, and ineffective communication with healthcare professionals. Education is therefore a crucial element of successful asthma management.\n\nRecently, the use of digital tools such as animated videos has become increasingly popular in pediatric education due to their engaging and interactive nature. Studies have shown that visual and interactive materials can improve knowledge, satisfaction, and adherence in children with chronic illnesses.\n\nThis randomized controlled study aims to evaluate the effect of an educational intervention using an animated video and booklet on asthma control and medication compliance in children aged 7-11 diagnosed with asthma. It is expected that this child-friendly, visually enriched educational approach will enhance asthma management and support medication adherence in children.",[27],[263],"pediatric","2025-04-07",{"date":266,"type":36},"2025-04-08",{"date":268,"type":21},"2025-05-15",{"date":270,"type":21},"2025-10-15",{"name":272,"class":123},"Trakya University",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":200,"sex":281,"minAge":282,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":285,"conditions":286,"keywords":298,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":313,"locationsCount":98},"100569575","aylo---autoimmunity-and-loss-of-y-100569575","NCT06696027","AYLo - AutoimmunitY and Loss of y","Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases","AYLo","Inclusion Criteria:\n\n* Male\n* \\> 50 years\n* Diagnosis of arthritis (RA, PsA), collagen diseases (SLE, systemic sclerosis, Sjögren's syndrome, mixed connective tissue diseases), vasculitis (eGPA, GPA, MPA, IgG4-related disease, GCA, PMR), sarcoidosis, COPD, ILD or asthma bronchiale confirmed by the treating physician.\n\nExclusion Criteria:\n\n* Female\n* \\\u003C 50 years\n\nInclusion Criteria (Healthy controls):\n\n* Male\n* \\> 50 years\n\nExclusion Criteria (Healthy controls):\n\n* Female\n* \\\u003C 50 years\n* autoimmune, rheumatological diease\n* pulmonary precondition","MALE","50 Years",{"count":284,"type":21},500,"The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic mutations, such as hematopoietic (mosaic) loss of the Y chromosome (mLOY), focusing on their underlying causes, pathophysiological significance, patterns of manifestation, and impact on disease progression in autoimmune, rheumatologic disorders. This research seeks to bridge existing knowledge gaps by exploring how such mutations influence immune homeostasis, cellular function, and susceptibility to inflammation-driven pathologies.\n\nThrough the integration of advanced immunological profiling, the study aspires to uncover key mechanisms that drive the initiation, progression, and complications of autoimmune rheumatic diseases. These analyses will combine single nucleotide polymorphisms (SNP) arrays, multiplex assays, transcriptomics, and flow cytometry staining of peripheral blood mononuclear cells to delineate the interplay between hematopoietic mutations and immune dysregulation.\n\nA further objective is the development of a multimodal framework for disease-specific characterization, enabling precise mapping of mutation-driven phenotypes across diverse autoimmune conditions. This framework will incorporate clinical, molecular, and imaging data.\n\nAdditionally, the AYLo study aims to explore the potential role of mLOY and other hematopoietic mutations as biomarkers for disease stratification, prognosis, and therapeutic response. The findings may open avenues for personalized treatment approaches, leveraging the molecular insights to inform targeted interventions and improve patient outcomes in autoimmune rheumatic disorders.\n\nBy integrating translational and basic science approaches, this study has the potential to redefine current paradigms in autoimmune disease research and therapy.",[287,288,289,290,291,292,293,294,295,296,297,27,55],"Giant Cell Arteritis (GCA)","Polymyalgia Rheumatica (PMR)","ANCA Associated Vasculitis (AAV)","Idiopathic Inflammatory Myopathies","IgG4-Related Diseases","Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Connective Tissue Disease","Sarcoidosis","Interstitial Lung Disease Due to Systemic Disease (Disorder)","Interstitial Lung Disease (ILD)",[299,300,301,302,303,304,290,291,305,306,294,295,307],"Autoimmune Diseases","Vasculitis","Large Vessel Vasculitis","Giant Cell Arteritis","Polymyalgia Rheumatica","ANCA Associated Vasculitis","Rheumatoid Arthritis","Psoriatic Arthritis","Interstitial Lung Disease",{"date":309,"type":36},"2025-04-10",{"date":311,"type":36},"2024-11-15",{"date":40,"type":21},{"name":314,"class":123},"University of Bonn",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":200,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":135,"phases":324,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":98},"100584586","pulmonary-deposition-of-ultrasound-rock-salt-aerosol-inhalation-therapy-100584586","NCT06891274","Pulmonary Deposition of Ultrasound Rock Salt Aerosol Inhalation Therapy","Study on the Lung Aerosol Deposition of Ultrasonic Rock Salt Inhalation Therapy","Inclusion Criteria:\n\nHealthy volunteers; Patients with chronic airway disease requiring nebulization therapy.\n\nExclusion Criteria:\n\nThose aged \\\u003C 18 years; Refusing to participate in the study; Patients requiring invasive ventilator assisted breathing; Patients with artificial airways. Patients with chronic liver and kidney function injury. Allergic to radioactive elements.",{"count":323,"type":21},26,[137],"In the in vitro modeling phase, the investigators plan to use a realistic human upper respiratory tract model and an asymmetric ideal bronchial tree model. By combining 3D printing experiments with CFD simulations, the investigators will investigate the respiratory tract deposition rate and distribution of micro - moist particles in ultrasound rock salt aerosol inhalation therapy. This will be compared with a small - volume nebulizer to verify the effectiveness of ultrasound rock salt aerosol inhalation therapy and lay the foundation for further research on the application of this inhalation technique to other drug formulations.\n\nIn the clinical phase, the investigators plan to have subjects inhale radioactive aerosols and use PET\u002FCT imaging technology to assess the deposition rate of aerosol particles in the lungs. By quantitatively analyzing the images, the investigators will study their distribution characteristics in real human bodies to verify the accuracy of the in vitro models and the potential for clinical application.",[55,27,327],"Chronic Bronchitis",[329,330,331],"Ultrasound Rock Salt Aerosol Inhalation Therapy","Pulmonary deposition rate","small volume nebulizer","2025-03-17",{"date":334,"type":36},"2025-03-24",{"date":336,"type":21},"2025-03-31",{"date":338,"type":21},"2026-03-31",{"name":340,"class":123},"Jingen Xia",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":15,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":365},"100568205","investigation-of-fixed-triple-inhaled-combination-in-asthmatic-patients-in-a-real-life-setting-100568205","NCT06678191","Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting","Effectiveness of BDP\u002FFF\u002FG 172\u002F5\u002F9 Fixed Triple Combination on Symptom Scores in Asthma Patients After 6 Months Treatment","INCLUSION CRITERIA:\n\n* Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion\n* Patients ≥ 18 years of age in ambulatory care\n* Uncontrolled asthma according to the physician's clinical assessment despite the use of\n\n  1. LABA - high dose ICS OR\n  2. LABA - high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.\n* Patients who are eligible for the use of Trimbow 172\u002F5\u002F9 μg pMDI according to the SmPC and the financing protocol for asthma\n\n  1. At least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months\n  2. Uncontrolled asthma (ACT≤15)\n  3. FEV1\\\u003C80% at baseline\n* Inhaled asthma therapy was changed to Trimbow 172\u002F5\u002F9 μg pMDI no more than 1 week prior to OR on the day of study inclusion\n* Patient provided written, informed consent to study participation\n\nEXCLUSION CRITERIA:\n\n* Participation in any clinical trial within 30 days prior to enrolment\n* Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment\n* Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND\u002FOR another important clinical situation that may interfere with patient's compliance with the treatment.\n* Continuous use of oral (\\>5 mg prednisolone\u002Fday OR \\>4 mg methylprednisolone\u002Fday) OR intravenous corticosteroids CHMED\\_2024\u002F01 Prof. Dr. Lilla Tamási 8(17)\n* Use of continuous oxygen therapy\n* Any malignant disease in the last 5 years\n* Tuberculosis (active or anamnestic)\n* Actual or previous use of biologics for asthma treatment in the past 12 months\n* All exclusion criteria listed in Trimbow 172\u002F5\u002F9 μg pMDI SmPC",{"count":349,"type":21},800,"The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and quality of life. Also, there is scarcity of data regarding the phenotypes of asthmatics who benefit the most from the use of fixed triple combinations.",[352,27],"Asthma, Chronic Obstructive Pulmonary Disease (COPD)",[354,355,31],"Asthma therapy","Fixed triple inhalation treatment","2024-11-20",{"date":358,"type":36},"2024-11-22",{"date":360,"type":36},"2024-10-24",{"date":362,"type":21},"2027-08-31",{"name":364,"class":43},"Chiesi Hungary Ltd.",45,{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":17,"minAge":373,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":4},"100568752","research-on-the-characteristics-of-chronic-airway-diseases-asthma-copd-100568752","NCT06685315","Research on the Characteristics of Chronic Airway Diseases (asthma, COPD)","Research on the Syndrome Characteristics of Chronic Airway Diseases (asthma, Chronic Obstructive Pulmonary Disease) Based on Intelligent Algorithm Fusion of Phenotype Omics","Inclusion Criteria:\n\n* Meets the diagnostic criteria for asthma or COPD.\n* Age of athma range from 12 years to 80 years.Age of COPD range from 18 years to 80 years.\n* The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients with respiratory diseases such as interstitial lung disease, lung malignant tumor, lung infectious diseases, pneumothorax, pleural effusion, etc., which affect the syndrome differentiation.\n* Patients with combining severe cardiovascular and cerebrovascular diseases, severe liver and kidney diseases, severe hematological malignancies, etc., affecting syndrome differentiation.\n* Patients with delirium, dementia, various mental illnesses.","12 Years","80 Years",{"count":376,"type":21},10545,"This study will to investigate the correlation between the characteristics of the population with chronic airway diseases (asthma, chronic obstructive pulmonary disease) and syndromes, in order to reveal the disease and syndrome features of the population; Secondly, screening and identifying biomarkers for asthma and chronic obstructive pulmonary disease to provide a basis for precise prevention and treatment of the disease.",[27,379],"Chronic Obstructive Pulmonary Disease (COPD)",[25,381,382,383,384],"Chronic Obstructive Pulmonary Disease","Phenomics","Intelligent algorithms","Epidemiological investigation","2024-11-10",{"date":387,"type":36},"2024-11-12",{"date":389,"type":21},"2024-12-01",{"date":391,"type":21},"2028-07-31",{"name":393,"class":123},"Henan University of Traditional Chinese Medicine",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":135,"phases":402,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":412,"leadSponsor":413,"locationsCount":98},"100568303","phase-4-evaluating-the-impact-of-single-dose-tiotropium-on-allergen-induced-early-asthmatic-response-100568303","NCT06679465","Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response","Inclusion Criteria:\n\n* age (years) at least 18 years\n* no confounding health issue (i.e. no health conditions, other than asthma, that would put the participant at risk or affect data integrity as determined by the principal investigator)\n* baseline FEV1 ≥ 65% of predicted normal at Visit 1\n* evidence of atopy to an allergen suitable for inhalation challenge following skin prick testing such as house dust mite, grass, cat or horse\n* fall in FEV1 of ≥ 20% at a dose of methacholine ≤ 600mcg (methacholine PD20) at Visit 1\n* positive response to allergen inhalation challenge (fall in FEV1 of ≥ 15% after inhalation of allergen at a dilution 1:32 or more dillute.\n* absence of respiratory infection for at least 4 weeks prior to Visit 1\n* absence of significant worsening of asthma that requires health care intervention or prolonged change in medication due to allergen exposure (or other trigger) for at least 4 weeks prior to Visit 1\n* women of child-bearing potential shall not be pregnant or lactating\n* non-smoker (cigarettes, vaping); ex-smoker with \\\u003C10 pack year history allowed; cannabis use will be evaluated on a case-by-case basis\n* if on as needed budesonide\u002Fformoterol therapy, no reported use within 3 weeks prior to allergen challenge\n\nExclusion Criteria:\n\n* Smoker \\>10 pack year history",{"count":401,"type":21},10,[403],"PHASE4","Evaluate single dose (2 x 2.5mcg\u002Fpuff; total dose 5mcg) effect of tiotropium administered 30 minutes prior to allergen challenge on allergen-induced EAR assessed as the maximal % fall in FEV1 after allergen inhalation compared to that of single dose (two puffs) matched placebo administered 30 minutes prior to allergen challenge.",[27],[61,407,408],"Tiotropium","Early asthmatic response",{"date":410,"type":36},"2024-11-07",{"date":243,"type":21},{"date":189,"type":21},{"name":414,"class":123},"University of Saskatchewan"]